After whetting analysts' expectations on the deal-making front, he executed a series of small deals for experimental ophthalmology treatments--which fit well with his own professional background.
AstraZeneca is piecing together a team of contractors for its almost virtual neuroscience unit, and the company has signed up with ePharmaSolutions to create a network that will unite its many outsourcers.
Celerion is looking to amp up its share of the biologics and vaccine development markets, launching a new containment room at its Belfast facility that will allow it to compete for study contracts.
Gold nanoparticles, because of several inherent characteristics, make excellent drug delivery vehicles, and scientists around the world are now studying the way the tiny particles penetrate cell membranes based on their positive or negative surface charges.
Global concern is growing over the outbreak of H7N9 avian influenza in China. So far, 133 cases of H7N9 sickness have been confirmed, and at least 37 deaths are deaths are thought to have been caused by the disease.
It's one of the latest investments from the Microsoft chairman and world's richest man that focuses on supporting translation of discoveries into breakthroughs for patients.
After starting to gut most of its staff this week, Aveo Oncology has started down a longer path to potential approval of its top drug candidate tivozanib, for which the company no longer plans to develop for kidney cancer.
GlaxoSmithKline has launched a probe of a research study involving its employees from a research lab in Shanghai, China.
Verastem has changed CEOs as the company seeks to translate stem cell discoveries into powerful new cancer drugs. Biotech entrepreneur and Verastem co-founder Christoph Westphal is stepping down from the chief executive post, and president and COO Robert Forrester will take the top job at the company and join the board of directors on July 1.
C.R. Bard is working hard to show the versatility of its Lutonix drug-coated balloon, even before it wins FDA approval. A few years after acquiring the technology in a $225 million grab of a company with the same name, the first human patient has joined a new trial testing the device below the knee.